8-K: TriSalus Life Sciences Reports Strong Preliminary Q4 and Full Year 2024 Results, Anticipates Profitability in 2025

TriSalus Life Sciences announced preliminary unaudited results showing significant revenue growth in 2024 and expects to achieve positive EBITDA and cash flow in 2025.

Summary

• TriSalus Life Sciences reported preliminary unaudited fourth quarter revenue of approximately $8.3 million, representing a 44% increase compared to the same period in 2023.
• Full year 2024 revenue reached approximately $29.4 million, a 59% increase year-over-year.
• The company's revenue is solely driven by sales of the TriNav Infusion System.
• Operating cash flow for the fourth quarter improved to approximately -$5.6 million, compared to -$10.8 million in the previous quarter.
• TriSalus expects revenue to grow by more than 50% in 2025.
• The company anticipates achieving positive full-year EBITDA in 2025 and positive cash flow during the second half of 2025.
• As of December 31, 2024, the company had approximately $8.5 million in cash and cash equivalents.
• TriSalus expects to receive an additional $10 million from its existing debt agreement with OrbiMed in the first quarter of 2025, which they believe will provide sufficient liquidity to fund operations through 2025.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong revenue growth, improved cash flow, and projections for profitability in 2025. The company's ability to secure additional funding also contributes to the positive outlook.

Positives

• The company experienced substantial revenue growth in both the fourth quarter and full year 2024.
• There was a significant improvement in operating cash flow in the fourth quarter compared to the third quarter.
• The company projects strong revenue growth for 2025.
• TriSalus expects to achieve positive EBITDA and cash flow in 2025.
• The company has secured additional funding to support operations through 2025.

Negatives

• The preliminary financial results are unaudited and subject to change.
• The company is still operating with negative cash flow, although it is improving.
• The company had approximately $8.5 million in cash and cash equivalents as of December 31, 2024, which is relatively low.

Risks

• The reported financial results may differ from the preliminary estimates.
• The company may not achieve its expected sales growth, EBITDA, and cash flow targets for 2025.
• The company may not be able to obtain additional liquidity if needed.
• There is a risk that the company may not continue as a going concern.
• The company operates in a competitive and rapidly changing environment.

Future Outlook

The company expects revenue to grow by more than 50% in 2025, achieve positive full-year EBITDA in 2025, and positive cash flow during the second half of 2025. They also expect to receive an additional $10 million in funding in Q1 2025.

Management Comments

• The company is pleased with the strong revenue growth in 2024.
• Management believes the company is on track to achieve profitability in 2025.
• The company expects to have sufficient liquidity to fund operations through 2025.

Industry Context

TriSalus operates in the competitive medical technology sector, specifically focusing on oncology and drug delivery. The company's growth is driven by its proprietary technology, which aims to improve therapeutic delivery to solid tumors. This announcement highlights the company's progress in a market with significant unmet needs.

Comparison to Industry Standards

• While specific competitor data is not provided in this document, the 59% revenue growth for the full year 2024 is significant and suggests strong market traction for TriSalus's technology.
• Companies like Sirtex Medical (acquired by CDH Investments) and Boston Scientific, which also focus on interventional oncology, could be considered as comparables, although their specific technologies and market focus may differ.
• The expectation of achieving positive EBITDA and cash flow in 2025 is a key milestone that would place TriSalus in a stronger position compared to many early-stage medical device companies.

Stakeholder Impact

• Shareholders are likely to react positively to the strong revenue growth and improved financial outlook.
• Employees may be encouraged by the company's progress and future prospects.
• Customers may benefit from the company's innovative technology and improved patient outcomes.
• Creditors may view the company as a lower risk due to its improved financial performance and outlook.
• Suppliers may see increased business opportunities as the company grows.

Next Steps

• The company will finalize its full financial results for the year ended December 31, 2024.
• A conference call and webcast will be held on March 27, 2025, to discuss the financial results and provide a business update.
• The company will continue to focus on growing revenue and achieving profitability in 2025.

Key Dates

Keywords

TriSalus, Financial Results, Revenue Growth, EBITDA, Cash Flow, TriNav Infusion System, Medical Technology, Oncology, Drug Delivery, OrbiMed